Vesa Tapiainen1,2, Piia Lavikainen1, Marjaana Koponen1,2,3, Heidi Taipale1,2,4,5, Antti Tanskanen4,5,6, Jari Tiihonen4,5, Sirpa Hartikainen1,2, Anna-Maija Tolppanen1,2. 1. School of Pharmacy, University of Eastern Finland, Kuopio, Finland. 2. Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland. 3. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. 4. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 5. Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland. 6. Impact Assessment Unit, National Institute for Health and Welfare, Helsinki, Finland.
Abstract
BACKGROUND/ OBJECTIVES: Antipsychotic use is associated with risk of falls among older persons, but we are not aware of previous studies investigating risk of head injuries. We studied the association of antipsychotic use and risk of head injuries among community dwellers with Alzheimer's disease (AD). DESIGN: Nationwide register-based cohort study. SETTING: Medication Use and Alzheimer's Disease (MEDALZ) cohort, Finland. PARTICIPANTS: The MEDALZ cohort includes Finnish community dwellers who received clinically verified AD diagnosis in 2005 to 2011. Incident antipsychotic users were identified from the Prescription Register and matched with nonusers by age, sex, and time since AD diagnosis (21 795 matched pairs). Persons with prior head injury or history of schizophrenia were excluded. MEASUREMENTS: Outcomes were incident head injuries (International Classification of Diseases, Tenth Revision [ICD-10] codes S00-S09) and traumatic brain injuries (TBIs; ICD-10 codes S06.0-S06.9) resulting in a hospital admission (Hospital Discharge Register) or death (Causes of Death Register). Inverse probability of treatment (IPT) weighted Cox proportional hazard models were used to assess relative risks. RESULTS: Antipsychotic use was associated with an increased risk of head injuries (event rate per 100 person-years = 1.65 [95% confidence interval {CI} = 1.50-1.81] for users and 1.26 [95% CI = 1.16-1.37] for nonusers; IPT-weighted hazard ratio [HR] = 1.29 [95% CI = 1.14-1.47]) and TBIs (event rate per 100 person-years = 0.90 [95% CI = 0.79-1.02] for users and 0.72 [95% CI = 0.65-0.81] for nonusers; IPT-weighted HR = 1.22 [95% CI = 1.03-1.45]). Quetiapine users had higher risk of TBIs (IPT-weighted HR = 1.60 [95% CI = 1.15-2.22]) in comparison to risperidone users. CONCLUSIONS: These findings imply that in addition to previously reported adverse events and effects, antipsychotic use may increase the risk of head injuries and TBIs in persons with AD. Therefore, their use should be restricted to most severe neuropsychiatric symptoms, as recommended by the AGS Beers Criteria®. Additionally, higher relative risk of TBIs in quetiapine users compared to risperidone users should be confirmed in further studies. J Am Geriatr Soc 68:595-602, 2020.
BACKGROUND/ OBJECTIVES: Antipsychotic use is associated with risk of falls among older persons, but we are not aware of previous studies investigating risk of head injuries. We studied the association of antipsychotic use and risk of head injuries among community dwellers with Alzheimer's disease (AD). DESIGN: Nationwide register-based cohort study. SETTING: Medication Use and Alzheimer's Disease (MEDALZ) cohort, Finland. PARTICIPANTS: The MEDALZ cohort includes Finnish community dwellers who received clinically verified AD diagnosis in 2005 to 2011. Incident antipsychotic users were identified from the Prescription Register and matched with nonusers by age, sex, and time since AD diagnosis (21 795 matched pairs). Persons with prior head injury or history of schizophrenia were excluded. MEASUREMENTS: Outcomes were incident head injuries (International Classification of Diseases, Tenth Revision [ICD-10] codes S00-S09) and traumatic brain injuries (TBIs; ICD-10 codes S06.0-S06.9) resulting in a hospital admission (Hospital Discharge Register) or death (Causes of Death Register). Inverse probability of treatment (IPT) weighted Cox proportional hazard models were used to assess relative risks. RESULTS: Antipsychotic use was associated with an increased risk of head injuries (event rate per 100 person-years = 1.65 [95% confidence interval {CI} = 1.50-1.81] for users and 1.26 [95% CI = 1.16-1.37] for nonusers; IPT-weighted hazard ratio [HR] = 1.29 [95% CI = 1.14-1.47]) and TBIs (event rate per 100 person-years = 0.90 [95% CI = 0.79-1.02] for users and 0.72 [95% CI = 0.65-0.81] for nonusers; IPT-weighted HR = 1.22 [95% CI = 1.03-1.45]). Quetiapine users had higher risk of TBIs (IPT-weighted HR = 1.60 [95% CI = 1.15-2.22]) in comparison to risperidone users. CONCLUSIONS: These findings imply that in addition to previously reported adverse events and effects, antipsychotic use may increase the risk of head injuries and TBIs in persons with AD. Therefore, their use should be restricted to most severe neuropsychiatric symptoms, as recommended by the AGS Beers Criteria®. Additionally, higher relative risk of TBIs in quetiapine users compared to risperidone users should be confirmed in further studies. J Am Geriatr Soc 68:595-602, 2020.
Authors: Jenni Ilomäki; J Simon Bell; Adrienne Y L Chan; Anna-Maija Tolppanen; Hao Luo; Li Wei; Edward Chia-Cheng Lai; Ju-Young Shin; Giorgia De Paoli; Romin Pajouheshnia; Frederick K Ho; Lorenna Reynolds; Kui Kai Lau; Stephen Crystal; Wallis C Y Lau; Kenneth K C Man; Ruth Brauer; Esther W Chan; Chin-Yao Shen; Ju Hwan Kim; Terry Y S Lum; Sirpa Hartikainen; Marjaana Koponen; Evelien Rooke; Marloes Bazelier; Olaf Klungel; Soko Setoguchi; Jill P Pell; Sharon Cook; Ian C K Wong Journal: CNS Drugs Date: 2020-09 Impact factor: 5.749
Authors: Howard Fillit; Myrlene S Aigbogun; Patrick Gagnon-Sanschagrin; Martin Cloutier; Mikhaïl Davidson; Elizabeth Serra; Annie Guérin; Ross A Baker; Christy R Houle; George Grossberg Journal: Int J Geriatr Psychiatry Date: 2021-08-27 Impact factor: 3.850